InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by Rosenblum Mark J, Chief Financial Officer. Officer active across 1 companies, notably Salarius Pharmaceuticals, Inc.. In total, 7 disclosures have been recorded. Total volume traded: €32k. The latest transaction was disclosed on 31 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations7 total
€4,69528,000 shares@ €0.16779.0% of flow
Common Stock
SEC:0001615219-22-000085:0·
Ideal exit: 25 Feb 2023 (T+270)
€1,76910,000 shares@ €0.17693.4% of flow
Common Stock
SEC:0001615219-22-000067:0·
€26,82876,246 shares@ €0.351951.7% of flow
Common Stock
SEC:0001615219-22-000019:0·
Ideal exit: 28 Nov 2022 (T+270)
€4,8287,787 shares@ €0.620151.8% of flow
Common Stock
SEC:0001615219-21-000095·
€4,8287,787 shares@ €0.62019.3% of flow
Common Stock
SEC:0001615219-21-000095:0·
€4,4969,563 shares@ €0.470148.2% of flow
Common Stock
SEC:0001615219-21-000042·
€4,4969,563 shares@ €0.47018.7% of flow
Common Stock
SEC:0001615219-21-000042:0·
7 of 7 declarations
About Rosenblum Mark J
Mark J. Rosenblum is Executive Vice President and Chief Financial Officer at Salarius Pharmaceuticals, Inc. He oversees the financial operations of the company, ensuring effective resource management and contributing to financial strategy. His role is essential for the financial health of the organization.
